https://www.dovepress.com/articles.php?article_id=31288
Authors Huang H, Chen L, Zou Q, Han F, Sun T, Mao G, He X
Received 25 June 2016
Accepted for publication 24 August 2016
Published 13 February 2017 Volume 2017:5 Pages 39—46
DOI https://doi.org/10.2147/JN.S115756
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Hari Shanker Sharma
Received 25 June 2016
Accepted for publication 24 August 2016
Published 13 February 2017 Volume 2017:5 Pages 39—46
DOI https://doi.org/10.2147/JN.S115756
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Hari Shanker Sharma
1Institute of Neurorestoratology, General Hospital of Armed Police Forces, 2Department of Neurosurgery, Yuquan Hospital, Tsinghua University, Beijing, 3Guangdong 999 Brain Hospital, Guangzhou, 4Centre for Stem Cells and Regenerative Medicine, Affiliated Hospital of Taishan Medical University, Liaocheng, Shandong, 5Department of Orthopedics, Beijing Army General Hospital, Beijing, 6Second Department of Orthopedics, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China
On behalf of the Chinese Association of Neurorestoratology and Chinese Branch of the International Association of Neurorestoratology
Abstract: Cell therapy has been shown to be a key clinical therapeutic option for central nervous system disease or damage, and >30 types of cells have been identified through preclinical studies as having the capacity for neurorestoration. To standardize the clinical procedures of cell therapy as one of the strategies for treating neurological disorders, the first set of guidelines governing the clinical application of neurorestoration was completed in 2011 by the Chinese Branch of the International Association of Neurorestoratology. Given the rapidly advancing state of the field, the Neurorestoratology Professional Committee of Chinese Medical Doctor Association (Chinese Association of Neurorestoratology) and the Chinese Branch of the International Association of Neurorestoratology have approved the current version known as the “Clinical Cell Therapy Guidelines for Neurorestoration (China Version 2016)”. We hope this guideline will reflect the most recent results demonstrated in preclinical research, transnational studies, and evidence-based clinical studies, as well as guide clinical practice in applying cell therapy for neurorestoration.
Keywords: cell therapy, neurorestoration, China, clinical application
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial
uses of the work are permitted without any further permission from Dove
Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2
and 5 of our Terms.
Download Article [PDF]
No comments:
Post a Comment